Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Role of neurofilament light polypeptide in head and neck cancer chemoresistance.

Chen B, Chen J, House MG, Cullen KJ, Nephew KP, Guo Z.

Mol Cancer Res. 2012 Mar;10(3):305-15. doi: 10.1158/1541-7786.MCR-11-0300. Epub 2012 Jan 13.

2.

Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.

Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR.

J Natl Cancer Inst. 2006 Feb 1;98(3):181-9.

PMID:
16449678
3.

IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.

Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.

Oncogene. 2010 Mar 18;29(11):1681-90. doi: 10.1038/onc.2009.454. Epub 2009 Dec 21.

PMID:
20023704
4.

SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.

Huang Z, Li H, Huang Q, Chen D, Han J, Wang L, Pan C, Chen W, House MG, Nephew KP, Guo Z.

Mol Carcinog. 2014 Oct;53(10):777-86. doi: 10.1002/mc.22033. Epub 2013 May 9.

PMID:
23661500
5.

Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A.

BMC Cancer. 2008 Jun 6;8:163. doi: 10.1186/1471-2407-8-163.

6.

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT.

Clin Cancer Res. 2004 Dec 15;10(24):8204-13.

7.

XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer.

Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, Han ZG, Guo W, Chen WT, Zhang P.

PLoS One. 2012;7(3):e31601. doi: 10.1371/journal.pone.0031601. Epub 2012 Mar 5.

8.

Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.

Li W, Melton DW.

Oncogene. 2012 May 10;31(19):2412-22. doi: 10.1038/onc.2011.426. Epub 2011 Sep 26.

PMID:
21996734
9.

Methylation of neurofilament light polypeptide promoter is associated with cell invasion and metastasis in NSCLC.

Shen Z, Chen B, Gan X, Hu W, Zhong G, Li H, Xie X, Liu Y, Li H, Xu X, Huang Z, Chen J.

Biochem Biophys Res Commun. 2016 Feb 12;470(3):627-34. doi: 10.1016/j.bbrc.2016.01.094. Epub 2016 Jan 20.

PMID:
26801564
10.

Frequent gene hypermethylation in laryngeal cancer cell lines and the resistance to demethylation induction by plant polyphenols.

Paluszczak J, Krajka-Kuźniak V, Małecka Z, Jarmuż M, Kostrzewska-Poczekaj M, Grenman R, Baer-Dubowska W.

Toxicol In Vitro. 2011 Feb;25(1):213-21. doi: 10.1016/j.tiv.2010.11.003. Epub 2010 Nov 13.

PMID:
21078381
11.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

12.
13.

Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer.

Wang PW, Abedini MR, Yang LX, Ding AA, Figeys D, Chang JY, Tsang BK, Shieh DB.

Int J Cancer. 2014 Dec 15;135(12):2760-9. doi: 10.1002/ijc.28928. Epub 2014 May 23.

14.

Targeting acid ceramidase sensitises head and neck cancer to cisplatin.

Roh JL, Park JY, Kim EH, Jang HJ.

Eur J Cancer. 2016 Jan;52:163-72. doi: 10.1016/j.ejca.2015.10.056. Epub 2015 Dec 11.

PMID:
26687835
15.

Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.

Zheng Y, Wang R, Song HZ, Pan BZ, Zhang YW, Chen LB.

Int J Biochem Cell Biol. 2013 Nov;45(11):2369-78. doi: 10.1016/j.biocel.2013.07.013. Epub 2013 Jul 24.

PMID:
23892093
16.

DNA promoter hypermethylation contributes to down-regulation of galactocerebrosidase gene in lung and head and neck cancers.

Peng J, Chen B, Shen Z, Deng H, Liu D, Xie X, Gan X, Xu X, Huang Z, Chen J.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11042-50. eCollection 2015.

17.

Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.

Su L, Wang Y, Xiao M, Lin Y, Yu L.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):484-91. doi: 10.1016/j.tripleo.2010.04.009.

PMID:
20868995
18.

TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer.

Wu X, Cao W, Wang X, Zhang J, Lv Z, Qin X, Wu Y, Chen W.

Mol Cancer. 2013 Dec 1;12(1):151. doi: 10.1186/1476-4598-12-151.

19.

N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.

Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.

J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131. Epub 2009 Jun 17.

PMID:
19535783
20.

Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.

Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA.

Mol Cancer Ther. 2010 Aug;9(8):2430-9. doi: 10.1158/1535-7163.MCT-10-0258. Epub 2010 Aug 3.

Supplemental Content

Support Center